PREPARATION OF SUSTAINED-RELEASE TIABROFENIC ACID BEADS

Abstract

Tiaprofenic acid (TA), has analgesic, anti-inflammatory and antipyretic
properties; it is an inhibitor of prostaglandin synthetase. The usual oral dose by
mouth is 600 mg daily; this may be given in 2 or 3 divided doses or once daily as a sustained-release preparation. TA is readily absorbed from the gastrointestinal tract. It has a short half-life of about 2 hours.
Sodium alginate is a natural, biodegradable and biocornpatible polymer used
as suspending and gelling agent in pharmaceutical technology. Recently, the alginate gel beads has received much attention in sustained-release preparation.
The aim of the present study was to formulate sustained-release TA beads
based on sodium alginate in order to reduce daily dose and to minimize gastrointestinal disturbance caused by the drug.
Key words: Tiaprofenic acid, sustained-release beads, sodium alginate.

Keywords

• -

PREPARATION OF SUSTAINED-RELEASE TIABROFENIC ACID BEADS

Abstract

Tiaprofenic acid (TA), has analgesic, anti-inflammatory and antipyretic properties; it is an inhibitor of prostaglandin synthetase. The usual oral dose by mouth is 600 mg daily; this may be given in 2 or 3 divided doses or once daily as a sustained-release preparation. TA is readily absorbed from the gastrointestinal tract. It has a short half-life of about 2 hours. Sodium alginate is a natural, biodegradable and biocornpatible polymer used as suspending and gelling agent in pharmaceutical technology. Recently, the alginate gel beads has received much attention in sustained-release preparation. The aim of the present study was to formulate sustained-release TA beads based on sodium alginate in order to reduce daily dose and to minimize gastrointestinal disturbance caused by the drug.

Keywords

• Tiaprofenic acid,sustained-release beads,sodium alginate.

References

1. 1. Martindale, The Extra Pharmacopoeia, 31 th Ed., p. 100, Royal Pharmaceutical Society, London, (1996)
2. 2. Aydin, Z., Akbuga, J., Int. J. Pharm., 137, 133-136 (1996).
3. 3. Munjeri, O., Collett, J.H., Fell, J.T., J. Control. Release 46, 273-278 (1997).
4. 4. Wan, L.S.C., Lim, L.Y., Soh, B.L., S.T.P.Pharm., 4, 195-200 (1994).
5. 5. Sezer, A.D., Akbuga, J., J. Microencapsul., 16, 195-203 (1999).
6. 6. Sezer, A.D., Akbuga, J., J. Microerrcapsul., 16,687-696 (1999).
7. 7. Santucci;F., Alhaique, Carafa, T., Coviello, T., Murtas, E., Riccieri, EM., J. Control. Release 42, 157-164 (1996).
8. 8. Ozsoy, Y., Bergigadi, N., Boll. Cfzim. Farnr., 139, 120-123 (2000).

9. 9. Wade, A., Weller, J., Handbook of Pharmaceutical Excipients, 2nd Ed., The American Pharmaceutical Association, p.10, Washington D.C., USA, 1994.
10. 10. Rajaonarivony, M., Vauthier, C., Couarraze, G., Puisieux, F., Couvreur, P., J. Plrarnz. Sci., 82,912 (1993).
11. 11. Tateshita, K., Sugawara, S., Imai, T., Otagiri, M., Biol. Pharm. Bull., 16,420-424 (1993).
12. 12. Tiirkoglu, M., Giirsoy, A., Eroglu, L., Okar, Y., S.T.P. Pllarnr., 7, 135-140 (1997).
13. 13. Kikuchi, A., Kawabuchi, M., Sugihara, M., Sakurai, Y., Okano, T., J. Control. Release, 47, 21-29 (1997).
14. 14. Takka, S., Acartiirk, F., Phartnazie, 54, 137-139 (1999).
15. 15. Imai, T., Kawasaki, C., Nishiyama, T., Otagari, M., Pharmazie 55,3218-222 (2000).
16. 16. Higuchi, T., J. Pharm. Sci., 52, 1145-1149 (1963).
17. 17. The United States Pharmacopeia XXLII, p.1791, United States Pharmacopeial Convention, Inc., (1995).